• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    3/19/25 8:31:07 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email
    false 0001022079 0001022079 2025-03-19 2025-03-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of Earliest Event Reported): March 19, 2025

     

    Quest Diagnostics Incorporated

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    Delaware

    (State or other jurisdiction of incorporation)

    001-12215   16-1387862
    (Commission File Number)   (I.R.S. Employer Identification No.)
    500 Plaza Drive    
    Secaucus, NJ   07094
    (Address of principal executive offices)   (Zip Code)
    (973) 520-2700

    (Registrant's telephone number, including area code) 

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.01 Par Value DGX New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

       

     

     

     

    Item 7.01. Regulation FD Disclosure

     

    On March 19, 2025, Quest Diagnostics Incorporated (the “Company”) will host an Investor Day during which members of the leadership team will discuss the Company's strategies to drive sustainable growth and deliver long-term shareholder value.

     

    In connection with Investor Day, the Company issued a press release that, among other things, discusses its business strategy, reiterates its previously issued guidance for full-year 2025 and provides its long-term outlook beyond 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 of this Current Report on Form 8-K by reference. The Investor Day presentation materials that will be used by members of the Company’s leadership team, which include information regarding the matters discussed by the Company at Investor Day and in the press release, have been posted on the “Events and Presentations” page of the Company’s investor relations website.

     

    The information in the preceding paragraphs, as well as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references this Current Report on Form 8-K. Information included on our website shall not be deemed to be incorporated into this Current Report on Form 8-K.

     

    The statements in the Investor Day press release and related presentation materials which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

     

    Item 9.01. Financial Statements and Exhibits

    d. Exhibit  
         
      99.1 Press release of the Company, dated March 19, 2025
      104 The cover page from this current report on Form 8-K, formatted in Inline XBRL.
         
         
         

     

     

       

     

     

     

    Signature

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    March 19, 2025

     

     

    QUEST DIAGNOSTICS INCORPORATED
       
    By: /s/ Sean D. Mersten
      Sean D. Mersten
      Vice President and Corporate Secretary 
       

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $DGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Quest Diagnostics Incorporated

    3 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    3/11/26 6:03:47 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Quest Diagnostics Incorporated

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    3/11/26 6:05:01 PM ET
    $DGX
    Medical Specialities
    Health Care

    Executive Vice President & CFO Samad Sam was granted 13,947 shares and covered exercise/tax liability with 7,720 shares, increasing direct ownership by 23% to 33,268 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    3/6/26 4:45:16 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

    New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risksSECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider.  Available now to all adult users of the company's secure, free patient mobile app and portal MyQuest, individuals can enga

    3/2/26 9:02:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer

    Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive teamSECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and acquisitions (M&A), has joined the company as senior vice president, chief strategy and M&A officer. In this role, Mr. Beauvalot is responsible for developing the company's gr

    2/26/26 8:24:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference

    SECAUCUS, N.J., Feb. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, 2026, at 8:00 a.m. Eastern Time. The Fireside Chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagn

    2/25/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    SEC Filings

    View All

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    3/2/26 2:21:02 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Quest Diagnostics Incorporated

    10-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    2/26/26 4:38:46 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    2/10/26 6:53:25 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

    Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno

    2/10/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

    SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's

    2/10/26 6:33:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

    SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast

    1/8/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care